75665-88-2

Basic information

• Product Name: Ethanone, 1-[5-Methoxy-2-nitro-4-(phenylMethoxy)phenyl]-
• Synonyms: Ethanone, 1-[5-Methoxy-2-nitro-4-(phenylMethoxy)phenyl]-;6-Nitro-O-benzylacetovanillone;1-(4-Benzyloxy-5-methoxy-2-nitro-phenyl)-ethanone
• CAS NO: 75665-88-2
• Molecular Formula: C₁₆H₁₅NO₅
• Molecular Weight: 301.294
• Mol File: 75665-88-2.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 488.1±40.0 °C(Predicted)
• Appearance: /
• Density: 1.247±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Ethanone, 1-[5-Methoxy-2-nitro-4-(phenylMethoxy)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 1-[5-Methoxy-2-nitro-4-(phenylMethoxy)phenyl]-(75665-88-2)
• EPA Substance Registry System: Ethanone, 1-[5-Methoxy-2-nitro-4-(phenylMethoxy)phenyl]-(75665-88-2)

Safety Data

• Hazardous Substances Data: 75665-88-2(Hazardous Substances Data)

Usage

General Description

Ethanone, 1-[5-methoxy-2-nitro-4-(phenylmethoxy)phenyl]-, also known as 5-MeO-DiPT, is a synthetic chemical compound that belongs to the tryptamine class. It is a psychedelic hallucinogen and is structurally related to dimethyltryptamine. 5-MeO-DiPT is known to produce profound sensory distortions, intense visual and auditory hallucinations, and altered states of consciousness. It is psychoactive and may have the potential for misuse and abuse. The chemical has been listed as a controlled substance in some countries and its sale and possession are regulated. Its effects on the human body and long-term health consequences are not fully understood.

Upstream product

• 1835-11-6 4-benzyloxy-3-methoxyacetophenone 
• 100-39-0 benzyl bromide 
• 498-02-2 1-(3-methoxy-4-hydroxyphenyl)ethanone 

Downstream Products

• 418759-58-7 1-(4-hydroxy-5-methoxy-2-nitrophenyl)ethan-1-one 
• 75665-73-5 1-(2-amino-4-(benzyloxy)-5-methoxyphenyl)ethanone 
• 1260586-85-3 2-methyl-2-(5-methoxy-2-nitro-4-propargyloxyphenyl)-1,3-dioxolane 
• 1260586-86-4 2-(5-methoxy-2-nitro-4-propargyloxy-α-methylbenzyloxy)ethanol 
• 1260586-89-7 C₆₅H₉₄N₂O₁₈ 
• 479690-03-4 7-benzyloxy-4-(2-fluoro-4-nitro-phenoxy)-6-methyloxyquinoline 
• 286371-49-1 7-(benzyloxy)-4-chloro-6-methoxyquinoline 
• 205448-29-9 6-methoxy-7-benzyloxy-4(1H)-quinolinone 
• 479690-08-9 1-(2-fluoro-4-nitrophenyl)-6-hydroxy-7-methoxy-quinoline 
• 417725-03-2 7-(benzyloxy)-6-methoxy-4-(4-nitrophenoxy)quinoline 
• 205448-29-9 7-benzyloxy-4-hydroxy-6-methoxyquinoline 
• 1355031-15-0 4-(4-aminophenoxy)-6-methoxyquinolin-7-ol 
• 1394821-14-7 N-(4-((7-hydroxy-6-methoxyquinolin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 
• 1394820-93-9 N-(4-((7-(2-hydroxy-2-methylpropoxy)-6-methoxyquinolin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 

Relevant articles and documents

Heterocyclic compound, preparation method and application thereof

The invention relates to a heterocyclic compound in the technical field of medicines. The compound is represented by a structural general formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, X, Y, Z, Cy1, Cy2, m, n and t have the meanings given in the specification; in addition, the invention also discloses an application of the compound and the pharmaceuticallyacceptable salt thereof in preparation of drugs for treating diseases caused by abnormal high expression of tyrosine kinase, especially application in preparation of drugs for treating and preventingcancers.

CARBAMATE AND UREA COMPOUNDS AS MULTIKINASE INHIBITORS

The present disclosure describes carbamate and urea compounds as novel multikinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such multikinase inhibitors and methods of using them for treating cancer, infectious diseases, and other disorders associated with kinases are also described.

Design and Construction of a Smart Targeting Drug Delivery System Based on Phototriggered Competition of Host–Guest Interaction

A smart targeting drug delivery nanocarrier is successfully constructed based on phototriggered competition of host–guest interaction. The targeting motif, i.e., biotin is first concealed by β-cyclodextrin (β-CD) via host–guest interaction. When the nanoparticles are exposed to UV light, the cleavage of photosensitive groups results in the exposure of adamantane (Ad) groups initially located in the interior of nanoassemblies, and β-CDs capped on biotin ligands can be replaced by Ad because of the higher binding constant between Ad and β-CD than that between biotin and β-CD. The competition of host–guest interaction leads to the recovery of targeting capacity of biotin ligands on the nanocarriers. By virtue of photoregulation, the nanocarriers exhibit controllable ligand-receptor recognition, which is proved by flow cytometry, laser confocal microscopy, and cytotoxicity assay. This strategy has a potential to improve the selectivity and safety of targeting drug delivery systems.